Here, we review the existing and emerging interventions for PD with focus on newly approved and investigational drugs for motor symptoms, motor fluctuations, dyskinesia, and balance and gait dysfunction.Similar content being viewed by others Therapeutic Strategies to Treat or Prevent Off Episodes in ...
Rytelo Approved for Lower-Risk Myelodysplastic Syndromes (MDS) with AnemiaIn June, the FDA approved Geron Corporation’s Rytelo (imetelstat) infusion to treat adults with low to intermediate-1 risk myelodysplastic syndromes (MDS) with anemia. Eligible patients have not responded to, have stopped ...
Oncology Drugs Approved by the FDA in June 2024 Throughout the month of June, several cancer therapies have received FDA approval for diseases including thyroid cancer, myelodysplastic syndrome (MDS), colorectal cancer (CRC), endometrial cancer, and follicular lymphoma (FL). Here...
If the product is a combination, it is either a novel combination of already approved drugs or at least one of its active ingredients is a novel compound that is approved for the first time. Drug exclusion criteria: The molecule is a new formulation of an already approved medicine. It rec...
metastasis, and enhance the accuracy, safety, and controllability of targeted drugs. Recently, advancements have been made in the use of KRAS inhibitors. BiAbs are expected to replace monoclonal antibodies as a mainstream therapy. By 2025, CAR-T therapy is expected to be approved for solid ...
FDA approved a REMS for thalidomide to ensure that the benefits outweigh the risks. The REMS may apply to one or more preparations of thalidomide and consists of the following: elements to assure safe use and implementation system. See https://www.accessdata.fda.gov/scripts/cder/rems/.Warning...
However, many new drugs are already showing significant single-agent activity in MM in phase 1 and 2 clinical trials, and hence there is a high likelihood that they will be eventually approved for the treatment of the disease in the near future. The development of these agents for regulatory...
Why has Revolade been approved? The Committee for Medicinal Products for Human Use (CHMP) decided that Revolade’s benefits are greater than its risks and recommended that it be given marketing authorisation.What measures are being taken to ensure the safe use of Revolade? The company that makes...
Two drugs were approved in January 2024: talazoparib tosilate for BRCA mutation-positive castration-resistant prostate cancer and breast cancer, and luspatercept for anemia associated with myelodysplastic syndrome (MDS). Talazoparib tosilate inhibits DNA repair in tumor cells, leading to cell death ...
Azacitidine (Vidaza®) is a pyrimidine nucleoside analogue of cytidine. Subcutaneous azacitidine was recently approved in the EU for the treatment of adults who are not eligible for haematopoietic stem cell transplantation and who have intermediate-2-risk or high-risk myelodysplastic syndromes (MDS) ...